



SUNDAY | MAY 15, 2022

## DON'T MISS

7-11:30 a.m.  
Room 262  
Residents Forum

7:30-9:30 a.m.  
Room 204  
Complications of Robotic  
Urological Surgery:  
Prevention, Recognition and  
Management


8:45-9:05 a.m.  
Great Hall A  
John Duckett Memorial  
Lecture: Lifelong Learning,  
What's in It for Me?

10-10:20 a.m.  
Great Hall A  
Panel Discussion: The Impact  
of the Internet on Sexual  
Medicine

10:30-11:45 a.m.  
Room 228  
Surgical Technology &  
Simulation: Training & Skills  
Assessment

1-2 p.m.  
S&T Hall, Booth 1521  
Residents Bowl: Finals

1-3 p.m.  
Room 344  
Research Forum: Early  
Career Investigators  
Showcase



## PATIENT ENGAGEMENT DRIVES IMPROVED HEALTH CARE DELIVERY AND RESEARCH

The practice of urology takes teamwork, with patients being valued members of the team. Still, patients often aren't included in clinical discussions, treatment recommendations, research prioritization, or research design and conduct.

"It's equivalent to developing a consumer product without factoring consumer needs into product development and marketing," said Angela Smith, MD, director of urologic oncology at the UNC Lineberger Comprehensive Cancer Center in Chapel Hill, North Carolina, during Saturday's Journal of Urology® Lecture 2022: "Engaging Patients: A Challenge to Our Care Delivery and Research Priorities."

If you neglect consumer needs and feedback, the product isn't apt to be a success. Medicine is similar. "We've been leaving the patient out for decades," Dr. Smith said. "It's no wonder over half of our clinical trials fail, due to issues such as lack of recruitment."

Patient engagement combines interventions designed to increase patient activation—their knowledge, skills and willingness to manage their own health care—to promote positive patient behavior, such as obtaining preventive care or exercising regularly. Patient engagement is one strategy to achieve the triple aim of improved health outcomes, better patient care and lower costs.

"Engaging patients is a challenge to our care delivery and research priorities, but it's worthy of our time because it can lead to better outcomes and can reduce costs," Dr. Smith said. "When patients are engaged in their own health care, they're likely to use fewer services."

How can you intentionally engage patients in your practice or institution? Dr. Smith offered these recommendations:

- **Direct care:** When providing patients with information about a diagnosis, ask them about their treatment plan preferences. With an engaged patient model, "treatment decisions are made based on medical evidence and your clinical judgment, but also on patients' preferences," Dr. Smith said.
- **Organizational design and governance:** Survey patients about their care experiences. Hospitals can involve patients as advisors or advisory council members. "Patients can co-lead hospital safety and quality improvement committees," Dr. Smith said.
- **Policy making:** A public agency can conduct focus groups with patients to ask opinions about a health care issue. Use patients' recommendations about research priorities to make funding decisions for allocating resources to health programs. "Have an actual patient on your committees that create policies," Dr. Smith said.



Intentional patient engagement also plays an important part in clinical research. "For urologists at the forefront of innovation, having studies that include the patient's voice helps channel which intervention to create and practice," Dr. Smith said.

"You can learn patient engagement skills and it doesn't take much effort," she added. Start by routinely asking three questions: Did we engage patients in shared decision making? Do we involve patients when optimizing our clinical operations or developing policy? Are patients involved in guideline development and dissemination? ●

// Engaging patients is a challenge to our care delivery and research priorities, but it's worthy of our time because it can lead to better outcomes and can reduce costs," Dr. Smith said. "When patients are engaged in their own health care, they're likely to use fewer services."

Angela Smith, MD

## INSIDE |


DISASTER RECOVERY **3** CROSSFIRE: TO TEST OR NOT TO TEST **3** RESIDUAL FRAGMENTS **4** KIDNEY TRANSPLANTS **6**  
EXHIBIT FLOOR MAP AND LISTING **8** ROBOTIC SURGICAL SYSTEMS **12** SOCIAL MEDIA **14**

**Focal One®**  
ROBOTIC FOCAL HIFU


Booth #117 | FocalOne.com




## How the iTind™ Procedure Works



**1** Implantation of the iTind device




**2** Treatment Period (5 to 7 days)



**3** Removal of the iTind device

## Reshaping BPH Treatment

- The iTind procedure involves a temporarily implanted nitinol device that reshapes the prostatic urethra and bladder neck to deliver significant and long-lasting relief of BPH symptoms, all without heating prostatic tissue or a permanent implant.<sup>1,2</sup> The iTind device can be placed in an outpatient or office setting using either a slim rigid or flexible cystoscope.
- Through continuous ischemic pressure and subsequent tissue necrosis, the iTind device struts slowly expand to reshape the prostatic urethra and bladder neck to better allow urine flow, while preserving erectile and ejaculatory function.<sup>1,2</sup>
- Post-op catheterization is rare, and patients are able to return home during the 5-7 day treatment, at the end of which the device is completely removed.<sup>1</sup>



**Before**

**After**



**Scan for more information**

**VISIT OLYMPUS BOOTH 537**

Implantation of the iTind device may cause urinary urgency, pelvic discomfort, dysuria or hematuria. In rare cases, iTind may cause urinary tract infection or acute urinary retention.

1. Amparore et al., 2021; 2. Chughtai et al., 2020



# DISASTER RECOVERY

## RESCUING LIGHT FROM DARKEST OUTCOMES

**C**autionary tales were on display as four surgeons shared the shock and awe behind some truly concerning complications during Saturday morning's plenary session.

Moderated by Randall Meacham, MD, professor and chief of the division of urology at the University of Colorado School of Medicine in Denver, "When Disaster Strikes Again: Preventing and Managing Nightmare Cases in Urology" gave attendees a behind-the-scenes look at a list of worst-case scenarios and some tips on how to avoid those issues in their own practices.

"This morning our colleagues are going into some of the very darkest places they've ever been in hopes that you and I never have to go there ourselves," Meacham said. "These heroes are going to show you some of the most bitter aspects of some truly concerning complications to keep you from experiencing the same bitterness in your own practice."

Tobias S. Kohler, MD, MPH, professor of urology at the

Mayo Clinic in Rochester, Minnesota, kicked off the session talking about a 27-year-old type 1 diabetic patient who came to his office with severe erectile dysfunction. The patient had elected to pursue penile implantation in order to have children with his fiancée, but because he'd already had a heart attack and bypass surgery, his case was complex.

"This was a pretty sick individual," Kohler said. "But he elected to pursue the implant because he wanted children."

Unfortunately, the first procedure didn't work and Kohler removed the device 16 hours after implantation.

"I was up all night worrying about [the patient]," he said. "I really thought the guy's penis might fall off."

The decision to remove the implant was the right one. The patient recovered and came back for a second attempt 13 months later. This time, Kohler said he opted for a smaller catheter, along with other tweaks, but in the end, the result was the same and he was forced to remove the device.



Tobias S. Kohler, MD, MPH

Fortunately, the story resulted in an odd but positive outcome.

"So he ends up back on my schedule and ... I open the door to the office and there his wife is holding a newborn baby," Kohler said. "I tried to appear not confused and offered my congratulations. [The patient] says, 'Doc, ever since you removed that second implant, my penis is hard enough for sex.' Turns out there was so much scar tissue from all the damage we'd done, they were able to have a child."

Brian W. Cross, MD,

associate professor of urologic oncology at the University of Oklahoma College of Medicine in Oklahoma City; Lindsay Hampson, MD, MAS, assistant professor at the University of California-San Francisco; and Rene Sotelo, MD, professor at the University of Southern California in Los Angeles, followed Kohler presenting cases focusing on (respectively) female organ-sparing cystectomy, suprapubic tube management gone awry, and how to best diagnose and treat superior mesenteric artery syndrome. ●

# CROSSFIRE: TO TEST OR NOT TO TEST

**D**o urologists really need stone analysis and metabolic urine testing? That was the question posed at Saturday afternoon's Crossfire: Controversies in Urology Debate: "Do We Really Need Stone Analysis and Metabolic Urine Testing?"

Moderated by Glenn M. Preminger, MD, professor of urologic surgery at Duke University Hospital in Durham, North Carolina, the Crossfire session teamed "Yea" panelists Justin Friedlander, MD, and Sara Best, MD, against the "Nay" team of Kymora Scotland, MD, PhD, and Ryan Hsi, MD.

Dr. Friedlander, director of endoscopic urologic surgery and the Comprehensive Kidney Stone Center at Albert Einstein Medical Center in Philadelphia, Pennsylvania, came out swinging, saying that yes, stone analysis and metabolic testing are needed for several reasons.

"It helps make the diagnosis; it helps reduce recurrence; it is cost-effective for our recurrent stone formers; and it helps with

compliance and management," Dr. Friedlander said. "It is also supported by the AUA guidelines and it gives hope to lifelong disease."

The AUA's current medical management guidelines include the following statements:

- When a stone is available, clinicians should obtain a stone analysis at least once. (Clinical Principle)
- Metabolic testing should consist of one or two 24-hour urine collections obtained on a random diet and analyzed at minimum for total volume, pH, calcium, oxalate, uric acid, citrate, sodium, potassium and creatinine. (Expert Opinion)

Dr. Scotland, assistant professor and endourologist at UCLA in Los Angeles, California, conceded that stone analysis and metabolic testing are guideline-supported items; provide patients with quantifiable targets; help with screening for rarer diseases like cystinuria and primary hypoxia; help noninvasively track patient compliance with fluids and medications; and give hope to patients who have a lifelong disease.



Kymora Scotland, MD

"But let's not forget the actual endpoint here," Dr. Scotland said. "[It] should be stone recurrence. There is no reason to do all of this if there is no effect on stone recurrence.

"It is my position that stone analysis and metabolic testing provide limited utility for most stone formers. [The tests] do not predict recurrence. They do not prevent recurrence, and they may, in fact, increase cost."

In her rebuttal statement, Dr. Best, an associate professor of urology at the



Justin Friedlander, MD

University of Wisconsin School of Medicine and Public Health in Madison, said the tests allow for cost-effective precision medicine, improve patient buy-in and maximize patient outcomes.

Dr. Hsi, an associate professor of urology at Vanderbilt University Medical Center in Nashville, Tennessee, countered by positing that the tests are challenging to interpret, uncommonly performed and impractical in certain clinical scenarios. ●



**The AUA Virtual Career Fair takes your career to new heights.**

**May 26, 2022 • 5-8pm ET**

- **Get one-on-one time with hiring employers**
- **Browse employer profiles**
- **View urology job openings**

**Learn more and register at:**



**American Urological Association JobFinder**

POWERED BY HEALTH ECAREERS

**Applications for AUA Diversity & Inclusion Chair**

The AUA is currently seeking a highly qualified member to fill the position of Diversity & Inclusion Chair beginning August 2022.

A job description with information about qualifications and time commitments will be posted online at **AUAnet.org/D&IChair**.

Applications will be accepted May 23 through June 16, 2022.

**American Urological Association**



American  
Urological  
Association

## 2022 AUA ANNUAL BUSINESS MEETING

HELD AT AUA2022

Monday, May 16 | 12PM  
Rivergate Room, Morial  
Convention Center

Everyone is invited to attend the AUA's Annual Business Meeting. The agenda includes reports of the President, Secretary, Treasurer, Bylaws Committee and Audit Subcommittee.

Agenda is available at  
[AUAnet.org/ABM](http://AUAnet.org/ABM)

# RESIDUAL FRAGMENTS: LEAVE OR CHASE?



Amy Krambeck, MD

**A**re clinically insignificant stone fragments (CIRFs) of less than or equal to 4 mm in the urinary system following an intervention, such as extracorporeal shock wave lithotripsy, ureteroscopy or percutaneous nephrolithotomy, truly clinically insignificant?

“Meta-analysis data indicate that about one-third of patients with residual fragments had a stone-related event requiring

reintervention,” said Amy Krambeck, MD, professor of urology and chief of the division of endourology/stone disease at Northwestern University in Chicago.

In Saturday's panel discussion, “Residual Fragments After Stone Surgery: Leave or Chase?,” Dr. Krambeck cited the literature to build a strong argument for removing residual fragments, including evidence that residual fragments of greater than 2 mm after percutaneous nephrolithotomy are associated with the need for more surgery, infectious complications, renal insufficiency and a poorer quality of life.

“The pain score in patients with small nonobstructing renal stone improved when they were stone-free,” Dr. Krambeck said.

Cost is another negative. Treating unplanned residual fragments costs roughly \$100 more than the fixed cost of a planned completion surgery for residual fragments.

Overall, “residual fragments are associated with increased stone events and the need for treatment, infectious events, decreased quality of life and increased health care costs,” she added.

Providing the counterargument for leaving CIRFs alone, Thomas Tailly, MD, PhD, a urologist-endourologist at the University Hospital of Ghent, Belgium, argued that the very definitions of “stone-free” and CIRF are themselves up for debate.

“What size residual fragment is acceptable to leave? What size residual fragment is insignificant? There's a lack of consensus,” Dr. Tailly said. Heterogeneity in data causes difficulties in defining residual fragments and their outcome during follow-up. “It's difficult to compare fragments head to head,” he said.

Moreover, Dr. Tailly argued that chasing residual stones of less than 4 mm is not cost-effective because residual

fragments of this size are not likely to require reintervention.

What about quality of life for patients who don't undergo residual fragment treatment? Dr. Tailly cited Wisconsin Quality of Life Index questionnaire data from 313 patients, 36.6% of whom had a median 7 mm stone after undergoing stone treatment. “Patients were less happy if they were treated for a residual fragment,” Dr. Tailly said.

Dr. Tailly argued that because most residual fragments of less than 4 mm won't need treatment, the routine treatment of residual fragments is more costly than observation.

“Quality of life is worse in patients who are treated for residual fragments, and adequate metabolic evaluation and preventive measures may reduce recurrence,” he said.

Whatever course you decide to take, to treat a CIRF or not, “It's important to engage the patient in the decision,” said moderator Daron Smith, MD. ●

*Urology Care*  
FOUNDATION™  
The Official Foundation of the  
American Urological Association

## Participate in the Urology Care Foundation's Virtual Auction!

### Ready, Set, Bid!

The Urology Care Foundation's auction is back and is 100% virtual! Bid on unique items including sports memorabilia, vacation packages, artwork and much more.

Proceeds from the auction will support the Urology Care Foundation's worldwide Research, Education and Humanitarian initiatives.

Bidding starts on May 1<sup>st</sup> and closes on May 17<sup>th</sup> at 5pm EST.

Visit [BidPal.net/UCF22](http://BidPal.net/UCF22) on May 1st to place your bids!

NOVELTIES


EXPERIENCES

EXCITEMENT

OUR GLOBAL  
MISSION

## GOLDSTEIN MICROSPIKE™ Approximator Clamps for Vasovasostomy and Vasoepididymostomy

- Ends clamp slippage.
- Will not damage mucosa.
- Can be adjusted and locked in any position.
- Folds in two directions to facilitate anterior and posterior wall anastomoses.
- Can be stabilized by attaching a hemostat or needle holder.



Marc Goldstein, MD, DSc (hon), FACS, Matthew P. Hardy Distinguished Professor of Reproductive Medicine and Urology Senior Scientist, Population Council Surgeon-in-Chief, Male Reproductive Medicine and Surgery Cornell Institute for Reproductive Medicine Weill Cornell Medical College of Cornell University New York-Presbyterian Hospital/Weill Cornell Medical Center

**assi**  
ACCURATE SURGICAL & SCIENTIFIC INSTRUMENTS®  
For diamond perfect performance®

accurate surgical & scientific instruments corporation  
800.645.3569 • 516.333.2570 • fax: 516.997.4948  
west coast: 800.255.9378 • Info: [assi@accuratesurgical.com](mailto:assi@accuratesurgical.com)  
Orders: [orders@accuratesurgical.com](mailto:orders@accuratesurgical.com) • [www.accuratesurgical.com](http://www.accuratesurgical.com)

Not all ASSI products shown in our literature or on our website are available for sale in Canada

AUA-2022  
New Orleans  
AUA News Online  
[auadailynews.org](http://auadailynews.org)



ModMed  
Urology

# It's about time to find your flow

**LOOKING FOR INNOVATIVE SOLUTIONS THAT ADDRESS PRODUCTIVITY,  
WORKFLOWS, PATIENT SATISFACTION AND STAFF RETENTION?**

**Stop by BOOTH #1609** to see the #1 urology-specific EHR and PM system\*  
that also includes Patient Engagement, Analytics and more.

***"To say that I  
absolutely love  
this program is an  
understatement."***

— SIJO J. PAREKATTIL, MD, MEDICAL DIRECTOR,  
AVANT CONCIERGE UROLOGY



Plus, enter our raffle to win a new Apple Watch 7 Series  
by signing up for a demo at BOOTH #1609!  
**[modmed.com/urology](https://modmed.com/urology)**



**ModMed**  
MODERNIZING MEDICINE

## NEW APPROACHES CAN IMPROVE KIDNEY TRANSPLANT NUMBERS WORLDWIDE

**T**he demand for kidney transplants far exceeds the supply of organs. A wait-listed kidney recipient can expect to wait five to seven years in North America and even longer in other parts of the world. New approaches to increasing the number of matched kidney donor-recipient pairs can increase transplantation rates and help patients get the lifesaving kidneys they need.

“Just in North America we have more than 100,000 patients on the kidney transplant wait-list,” said Alp Sener, MD, PhD, FRCSC, chair and chief of urology at Schulich School of Medicine & Dentistry, Western University, in London, Canada. “If you extrapolate this to the rest of the world, the numbers

can be staggering. Anything we can do to increase the number of potential donors will have a significant impact on the quality of life and lifespan of patients living with kidney disease.”

Dr. Sener will moderate the panel discussion “Novel Methods to Boost Kidney Transplantation Globally” on Monday from 1 to 1:20 p.m. Two panelists will discuss new approaches that may help increase the number of living donor kidneys available for transplantation.

Jeffrey Lorne Veale, MD, professor of urology at the University of California, Los Angeles David Geffen School of Medicine, has pioneered the use of a voucher system that effectively lets living donors give a kidney to a recipient today in return for a voucher that can later be redeemed for a future transplant by another person.

“The voucher could allow a parent whose child has a chronic kidney condition that will progress to transplantation at some point in the future

to donate a kidney now for a wait-listed recipient,” Dr. Sener said. “In return, the parent gets a voucher that guarantees an organ in the future when his or her child has progressed to needing a replacement organ, and the parent is no longer in prime physical condition to donate. That kind of flexibility has opened up transplantation numbers. Dr. Veale will discuss the program and share the data they have collected.”

Michael A. Rees, MD, PhD, professor of urology and director of renal transplantation at the University of Toledo Medical Center in Ohio, has taken an international approach to ensuring patients across many countries receive lifesaving organ transplants. “Dr. Rees founded a nonprofit organization that works with transplant centers to find matches for incompatible donor and recipient pairs,” said Dr. Sener. “This program has grown internationally and helps countries maximize paired donation programs.



Michael A. Rees, MD, PhD



Alp Sener, MD, PhD, FRCSC



Jeffrey Lorne Veale, MD

“Dr. Rees led the first global kidney exchange transplant in which a paired exchange mechanism was used to overcome the barrier of receiving a kidney transplant by a patient in another country,” he said. “Creating chains between donor-recipient pairs in North America and overseas can lead to better surgical outcomes for patients in underserved countries. In this manner, everyone wins.”

Both approaches that will be discussed at the plenary session are highly regarded in the transplant literature in North America, Dr. Sener added, but slightly less so in urology


because most of the transplants performed in North America are done by general surgery teams. It is important for urologists to know of the pioneering impact Drs. Rees and Veale are making on the global transplant community.

“Something as simple as voucher programs or the creation of international transplant chains can have a tremendous immediate impact on patient care and survival,” Dr. Sener said. “At the same time, they can have a multimillion-dollar impact on the total health care system by getting patients off of costly dialysis.” ●

**Panel Discussion: Novel Methods to Boost Kidney Transplantation Globally**  
Monday, May 16  
1-1:20 p.m.  
Great Hall A

# UROLIFT®

## THE RIGHT SOLUTION FOR MOST OF YOUR BPH PATIENTS\*



**Stop by Booth #323 during the AUA Exhibition Hours**

\*Contraindicated in men with current gross hematuria, urinary tract infection, urinary incontinence, urethral conditions that prevent device insertion, or a prostate volume greater than 100cc. Most common side effects are temporary and include hematuria, dysuria, micturition urgency, pelvic pain, and urge incontinence. Rare side effects, including bleeding and infection, may lead to a serious outcome and may require intervention. Refer to the Instructions for Use for a complete listing of the indications, contraindications, warnings and precautions.

1. Roehrborn, J Urol 2013

CAUTION: Federal (USA) law restricts this device to sale by or on the order of a physician.

Teleflex, the Teleflex logo, the UroLift logo, and the UroLift ATC logo are trademarks or registered trademarks of Teleflex Incorporated or its affiliates, in the U.S. and/or other countries.

©2022 Teleflex, Inc. All rights reserved. MAC02413-01 Rev A

**Scan QR Code to  
Learn More**



**Teleflex®**  
INTERVENTIONAL UROLOGY




# The Leading **Prostate Focal Therapy** Controlled by Urologists



Hands-On Simulations  
**Booth #117** | [FocalOne.com](http://FocalOne.com)

# EXHIBIT FLOOR MAP



## EXHIBITOR LISTING

### A

A&E Endoscopy..... 2008  
 A.M.I. Agency for Medical  
 Innovations GmbH..... 1044  
 AAAASF..... 2225  
 AbbVie ..... 725  
 ABC Home Medical Supply, INC. .... 2564  
 Accord BioPharma ..... 2343  
 Acerus Pharmaceuticals Corporation ..... 2245  
 Acerus Pharmaceuticals Corporation ..... 2639  
 Advance Medical Designs..... 2007  
 Advanced Accelerator Applications ..... 2630  
 Agiliti..... 1318  
 Akina Pharmacy ..... 1562  
 Alnylam Pharmaceuticals..... 2556  
 AmbiMedInc..... 1843  
 Ambry Genetics ..... 905  
 Ambu Inc..... 2001  
 Ambu Inc..... 2736  
 Ambu Inc..... 2741  
 America Medic & Science, AMS ..... 2065  
 American Medical Endoscopy/  
 Strauss Surgical..... 1928

AngioDynamics..... 1460  
 Antares Pharma, Inc..... 1455  
 Applaud Medical, Inc. .... 1862  
 Asclepion Laser Technologies GmbH ..... 2423  
 Asociación Urológica  
 de Centroamerica y Caribe (AUCA) ..... 2131  
 Aspirus Health ..... 1860  
 ASSI-Accurate Surgical & Scientific Inst..... 1805  
 Astellas Pharma US ..... 123  
 AstraZeneca..... 2661  
 AstraZeneca..... 2760  
 AstraZeneca..... 617  
 Auris Health..... 1207  
 Auris Health..... 2654  
 Avenda Health ..... 854  
 Axonics, Inc. .... 2145

### B

BARD1 Life Sciences Ltd..... 1841  
 Bayer ..... 1537  
 BD ..... 2627  
 BD ..... 2637  
 Best Medical International..... 1963  
 Biobot Surgical..... 2327  
 BioProtect Ltd. .... 1229

BioTE Medical ..... 1852  
 BK Medical ..... 1317  
 Blue Earth Diagnostics, Inc. .... 455  
 Bonraybio CO., LTD..... 1658  
 Boston Scientific ..... 137  
 Boston Scientific ..... 2537  
 Boston Scientific ..... 2649  
 Boston Scientific ..... 2651  
 Bostwick Laboratories ..... 929  
 Bright Uro ..... 2102  
 Bristol Myers Squibb ..... 2427  
 Bristol Myers Squibb ..... 2454  
 Butterfly Medical..... 857  
 Butterfly Network ..... 2355

### C

Calyxo, Inc. .... 2561  
 Canadian Urological Association ..... 1845  
 Candel Therapeutics ..... 1020  
 CareMed Specialty Pharmacy / Onco360  
 Oncology Pharmacy ..... 2425  
 CAREstream America ..... 2326  
 Caris Life Sciences..... 2328  
 Carle Health..... 2224  
 Case Recruiters, Inc..... 963  
 CellOxess Biotechnology ..... 1654  
 Celularity Inc..... 1759  
 CG Oncology, Inc..... 2526  
 CIVCO Medical Solutions ..... 2323



## THE SCIENCE & TECHNOLOGY HALL

### Hall Hours:

#### SUNDAY

9 a.m.-4 p.m.

Beer Tasting:  
2-4 p.m.

CHECK THE S&T HALL DAILY SCHEDULES  
OR MOBILE APP FOR INDUSTRY PROGRAMMING



Emerging Corner



Saturday Networking  
Event



Industry Clinical  
Update (ICU) Theater



Skills Enhancement  
Workshops




Robotics Theater



Skills Challenge





Food Court

2072

AUA Sections & Other Societies

1861 1859 1857 1855

1964 1962 1958 1956 1954

1963 1961 1959 1955 1953

2062 2060 2058 2056 2052

2065

2059

2053

2163 2161 2159 2155

2264 2260 2258 2254

2265

2253

2465 2463 2461 2459 2455

2566 2562 2560 2558 2556 2554

2573 2567 2561 2555

2672 2666 2661 2655

2673 2667 2665

2772 2768 2766 2756

2775 2773 2771 2765 2761 2759 2755

2361 2355

2460 2454

2349

2343

2339 2337

2438 2436

The Emerging Corner

2449 2439

2548 2540 2538

2549

2537

2651 2649

2748 2745 2743 2741 2737

2627

2623 2617

2722 2720 2718 2719

Beer Tasting

2725

1847 1845 1843 1841 1837

1946 1944 1942 1940 1936

1945

1937

2145

2137

2245

2237

International Societies Row

2131 2129 2127 2123 2121 2117

2230 2228 2226 2224 2222 2220 2216

2231 2229 2227 2225 2223 2221 2219 2217

2330 2328 2326 2324 2322 2320 2318 2316

2329 2327 2325 2323

2428 2426 2424 2422

2431 2429 2427 2425 2423 2421 2419 2417

2530 2528 2526 2524 2522 2520 2518 2516

2529 2527 2523

2630 2628 2626 2622

2627

2623 2617

2722 2720 2718

2725

2719

1829 1823 1821 1817

1928 1926 1924 1922 1916

1927

1917

2131 2129 2127 2123 2121 2117

2230 2228 2226 2224 2222 2220 2216

2231 2229 2227 2225 2223 2221 2219 2217

2330 2328 2326 2324 2322 2320 2318 2316

2329 2327 2325 2323

2428 2426 2424 2422

2431 2429 2427 2425 2423 2421 2419 2417

2530 2528 2526 2524 2522 2520 2518 2516

2529 2527 2523

2630 2628 2626 2622

2627

2623 2617

2722 2720 2718

2725

2719

1807 1805 1801

1908 1906 1904 1900

1909 1907 1905 1901

2008 2006 2004 2000

2009 2007 2005 2001

2110 2106 2104 2102 2100

2111 2109 2105 2101

Skills Enhancement Workshops

SEW #1

SEW #2

SEW #3

Clarity Diagnostics .....	2260
Clarus Therapeutics.....	1507
Cleveland Diagnostics, Inc.....	2530
Clinical Laserthermia Systems.....	364
Coloplast Corp.....	707
Coloplast Corp.....	2667
Coloplast Corp.....	2673
Coloplast Corp.....	2772
Combat Medical Ltd. ....	959
CompHealth .....	2110
Confederación Americana de Urología.....	2117
Connected Medical Services (CMS) .....	1760
Convergent Laser Technologies .....	1309
Cook Medical .....	1325
Cook MyoSite.....	1000
CoolBeans Underwear .....	2361
Corinth MedTech .....	955
Creative Medical Technology Holdings Inc..	2062
CS Surgical, Inc.....	2231

Dartmouth-Hitchcock.....	2056
Deep Bio.....	2161
Dendreon Pharmaceuticals LLC .....	1017
Department of Veterans Affairs.....	1856
Designs for Vision, Inc.....	911
Doctus Equipamentos Medicos Ltda.....	2417
Dornier MedTech .....	1637

Ecleris USA.....	2058
Edge Pharma .....	2318
Eigen Health .....	2349
Electro Medical Systems SA.....	1036
Elsevier .....	1008
EMD Serono / Pfizer Alliance.....	2229
Encore, Inc. ....	1961
Endo Pharmaceuticals .....	1301
Endo Pharmaceuticals .....	2737
Endoscopy Solutions .....	1946
Endourological Society, Inc. ....	1861
Ethicon .....	2461
European Association of Urology.....	1908
EVEXIAS Health Solutions.....	1762
Exact Sciences / Oncotype .....	647
Exact Sciences / Oncotype .....	2567
Exelixis, Inc.....	1945
Exosome Diagnostics.....	461

Fellow.....	2329
Firefly Global.....	1006
FirmTech Inc.....	2538
Focal Healthcare, Inc. ....	1936
Focal One .....	117
Focalyx, LLC .....	1555
Foundation Medicine, Inc.....	1709
Francis Medical .....	2666
Fujifilm.....	1701

Genentech.....	2005
GEOTEK Medical USA LLC.....	2324
Gilead Sciences, Inc.....	2428
Global Fair Play .....	2100
Global Medical Endoscopy .....	2000
GloShield .....	1959
GoPath Diagnostics.....	2053
GOTOP Medical, Inc.....	1022
Guangzhou Red Pine Medical Instrument Co., Ltd.....	2523
Guerbet, LLC .....	2317

Health Best International LLC .....	2006
Health First Medical Group.....	2429
HealthTronics, Inc.....	845
Hispanic Urology Society North America (HUSNA).....	1956
Huger Medical Instrument Co. Ltd .....	1056
Hunan Vathin Medical Instrument Co.,Ltd..	2216
Imagin Medical .....	2555
ImmunityBio, Inc.....	559
INB Medical .....	2109
Inform Diagnostics .....	2421
Infuserve America .....	1942
Innovex Medical.....	759
inReach Health.....	1361
Insightec .....	2465
Integra Life Sciences.....	2422
Intermountain Healthcare .....	2221
Intuitive .....	207
Intuitive .....	2759
Intuitive .....	2761
Invitae.....	2745
Irrisept .....	2111
Isoray.....	2516
IVUMed .....	1328

Jackson & Coker .....	2558
Janssen Biotech, Inc. ....	1023
Janssen Biotech, Inc. ....	2642
Janssen Biotech, Inc. ....	2672
Janssen Biotech, Inc. ....	2742
Japanese Urological Association .....	2127
KARL STORZ Endoscopy - America, Inc.....	1937
Kidney Cancer Association .....	2108
Koelis.....	1201
Laborie .....	517
Lantheus.....	1337
Lazarus 3D.....	1046
LiNA Medical .....	755
LithoLyte .....	701
LocumTenens.com .....	1821
LP Surgical Fibers .....	1916
LynxDx.....	1663

Male From Home .....	1064
Marshfield Clinic Health System .....	2060
McLeod Health .....	2259
Mcube Technology Co., Ltd.....	1847
MDxHealth .....	801
Med Fibers, Inc. ....	663
Medica S.p.A .....	1320
Medica S.p.A .....	2258
Medicus Healthcare Solutions .....	2562
Medifix Inc.....	1560
Mediflex Surgical Products .....	954
Mediplus.....	917
Medispec Ltd. ....	1355
Medpro .....	1217
Medtronic.....	1601
Melzi .....	1761
Memorial Healthcare System .....	2220
MenHealth.....	1858
Merck & Co., Inc. ....	1645
Merck & Co., Inc. ....	2655
Mercy Clinic.....	2718
MicroGenDX .....	1753
Mid-Atlantic Section of the AUA.....	1954
MIM Software Inc. ....	1026

miR Scientific .....	945
miR Scientific .....	2743
Mitaka USA .....	2623
Modernizing Medicine .....	1609
Modulight Corporation .....	2628
Molecular Lab Partners.....	1559
Molecular Testing Labs.....	1661
Moonstone Nutrition .....	1763
MPLT Healthcare .....	362
Multiphze LLC.....	859
My PCR Lab LLC.....	2626
Myovant Sciences and Pfizer Inc.....	1917
Myovant Sciences and Pfizer Inc.....	2543
Myovant Sciences and Pfizer Inc.....	2754
Myriad Genetics.....	2460
Myriad Genetics.....	2771
MysteryVibe.....	2223

NAED, Inc .....	1955
NanoEnTek America, Inc.....	961
Nanospectra Biosciences .....	958
National Ultrasound.....	2230
Neoscope2020.....	1461
NeoTract   Teleflex .....	323
New York Section of The American Urological Association, Inc. ....	1859
NextMed.....	109
NinoMed .....	1501
North Central Section of the AUA, Inc. / South Central Section of the AUA, Inc. ...	1962
Northwell Health.....	2438
Norton Children's Urology, affiliated with the U of L School of Medicine .....	2104
Novartis .....	2554

Ochsner Health .....	2463
Officite .....	1223
Ohio Valley Healthcare Solutions.....	1225
Olympus .....	537
OPERATION HAPPENIS .....	2222
OPKO Health, Inc. ....	747
Optical Integrity, Inc. ....	1060
Optum.....	2720
Oruba Technology & Innovation .....	2358
OSF HealthCare .....	2227
OTU Medical Inc. ....	1330

Pacey Medtech Ltd.....	2528
Pacific Edge Diagnostics .....	1829
Paige .....	2360
Palette Life Sciences.....	2264
Palette Life Sciences.....	2265
Panacea Financial.....	1324
Pathnostics .....	361
Pelvic Wave.....	2527
Perineologic.....	257
Pfizer Oncology.....	337
Pfizer Oncology.....	2643
Philips.....	717
Photocure .....	2237
Photocure .....	2755
Piedmont Healthcare.....	2524
Porter Instrument.....	1659
PracticeLink.com .....	2436
Practis.....	1316
Prairie Lakes Healthcare System.....	2419
Procept Biorobotics .....	147
Procept Biorobotics .....	2545
Procept Biorobotics .....	2549
ProEndoscopy .....	2325
Profound Medical .....	1447
Prologics Healthcare.....	1322
Promaxo .....	1009
Prometheus Group, The .....	1837
Promis Dx .....	1757
Prostate Conditions Education Council.....	1024
Prostatype Genomics AB .....	1365
Pusen Medical.....	101

## EXHIBITORS

continued from page 9

## Q-R

QDx Pathology Services.....	1801
Quanta System SPA.....	447
Quantib .....	1944
Quibim .....	2155
QuickChange/UI Medical.....	858
Qventus.....	2106
Reditus Laboratories, LLC .....	2253
Revive Rx .....	2165
RG Medical .....	2052
Rhosse Medical .....	2337
Richard Wolf Medical Instruments Corporation .....	1926
Richard Wolf Medical Instruments Corporation .....	1927
Rigicon, Inc. ....	1058
Rocamed .....	201
Rose Micro Solutions LLC .....	1030
Rose Micro Solutions LLC .....	2217
RosmanSearch .....	2004

## S

Sagent Urology.....	919
SCRUBS RRG.....	1219
Seagen, Inc. ....	1953
Seplou, Inc. ....	1940
SH MEDICAL CORP.....	901
Shanghai SeeGen Photoelectric Technology Co.,Ltd. ....	2424
Siemens Healthineers .....	2137
Signati Medical, Inc. ....	1823

Skagit Regional Health .....	2426
Sociedad Argentina de Urología.....	2121
Sociedad Colombiana de Urología .....	2129
Sociedade Brasileira de Urologia (SBU) .....	2123
Société Internationale d'Urologie (SIU) .....	1958
Society of Government Service Urologists (SGSU).....	1855
SoLá Pelvic Therapy.....	2560
Sonablate Corp.....	549
SonoMotion, Inc. ....	1909
Sontec Instruments .....	1900
Soundable Health .....	1924
Southeastern Section of the AUA, Inc. / Northeastern Section of the AUA, Inc. ...	1964
Specialty Networks, LLC .....	1221
Spectrum Health Lakeland .....	2518
Springfield Clinic.....	2159
SRS Medical Corp. ....	317
Stanford Medicine Technology Enabled Clinical Improvement (TECI) Center .....	2517
STERIS Corporation .....	1653
Stinger Endoscopy, LLC .....	2566
Strauss Surgical USA .....	2261
Stream Dx.....	1564
Stryker Endoscopy.....	2455
Sun Pharma .....	1901
Surgical Affiliates Management Group .....	1463
Surgical Science - Symbionix Simulators .....	1016
Surgitel.....	1905

## T

Telix Pharmaceuticals.....	655
Tempus.....	2163
Teradek.....	2722
Texas Health Resources .....	2522

The Flume Catheter Company.....	2439
The Gideons International.....	2459
The Guthrie Clinic .....	2226
The Permanente Medical Group .....	2622
Theator .....	1054
Theralogix.....	855
Tolmar Pharmaceuticals.....	527
TrackableMed .....	2009
Traverse Therapeutics .....	927

## U

Uberlube.....	2330
UC-CARE .....	921
UFM Underwear for Men .....	2431
UHS .....	2320
United Endoscopy .....	1807
United Medical Systems .....	1417
United States Navy Recruiting .....	2105
University Compounding Pharmacy.....	1547
Urethrotech .....	907
URO-1, Inc .....	923
UroChoice .....	2219
UroGen Pharma Inc.....	837
UroGen Pharma Inc.....	2775
Urology Surgical Consulting / Better Body MD .....	1758
Urology Times.....	1906
UrologyLocums.com .....	2449
Uromedica, Inc.....	2719
UroSystem Zrt. ....	2520
UROTRAINER .....	1904
Urotronic .....	1817
Urovant Sciences, Inc. ....	1001
Urovant Sciences, Inc. ....	2748
Urovant Sciences, Inc. ....	2768

UroViu Corporation .....	355
Utiva, by Szio+ .....	2254

## V

Valencia Technologies .....	2617
Vascular Technology.....	1409
Veracyte.....	1563
Verana Health .....	2529
Veru Inc .....	2059
Veru Inc .....	2765
Verve Medical, Inc.....	2747
Veterans Prostate Cancer .....	263
Viomerse .....	2101
Virtuoso Surgical Inc. ....	2548

## W

Wasatch Medical Specialties.....	2316
Weatherby Healthcare.....	2339
WebMD .....	925
Well Lead Medical Co. Ltd. ....	1347
Western Section American Urological Association Inc (AUA) .....	1857
Wolters Kluwer .....	909

## X-Y-Z

Xodus Medical.....	1465
Yuma Regional Medical Center .....	1062
Zenflow, Inc. ....	2573
Zimmer MedizinSystems.....	2322

Exhibitors list as of April 12, 2022



## The NEW Blue Light Powered by Saphira™

Elevate your experience with seamless transition between three imaging modalities:

- Brilliant White Light
- CHROMA Vascularity Enhancement
- Blue Light in Full HD

**STORZ**  
 KARL STORZ – ENDOSKOPIE

 KARL STORZ SE & Co. KG, Dr.-Karl-Storz-Straße 34, 78632 Tuttlingen/Germany  
 KARL STORZ Endoscopy-America, Inc. 2151 East Grand Avenue El Segundo, CA 90245-5017/USA  
 www.karlstorz.com

 American  
Urological  
Association

## 2022 AWARD WINNERS


**RAMON GUITERAS AWARD**  
 Glenn M. Preminger, MD  
 For outstanding service to the AUA and for pioneering and innovative work in the field of endourology

**HUGH HAMPTON YOUNG AWARD**  
 Arthur L. Burnett II, MD, MBA  
 For groundbreaking advances in male sexual health, as well as advocacy, diversity and humanitarian contributions

**GOLD CYSTOSCOPE AWARD**  
 Angela B. Smith, MD, MS  
 For outstanding leadership and contributions in bladder cancer and outcomes research

**MID-CAREER AWARD**  
 Kirsten L. Greene, MD, MS  
 For inspired institutional leadership, clinical expertise and service in the development of AUA guidelines

**LIFETIME ACHIEVEMENT AWARD**  
 Barry A. Kogan, MD  
 For outstanding leadership and contributions to the practice, science and education of pediatric urology

**EUGENE FULLER TRIENNIAL PROSTATE AWARD**  
 Claus G. Roehrborn, MD  
 For numerous contributions to the scientific study of BPH and its treatment

**VICTOR A. POLITANO AWARD**  
 Craig V. Comiter, MD  
 For a defining career centered on investigation, innovation and education in treating incontinence

**WILLIAM P. DIDUSCH ART & HISTORY AWARD**  
 Kevin R. Loughlin, MD, MBA  
 For demonstrating a passion for medical history and extensive publications on urological history

**DISTINGUISHED CONTRIBUTION AWARD**  
 Kevin R. Loughlin, MD, MBA  
 For outstanding contributions as AUA Research Chair, strengthening the pipeline of surgeon-scientists and researchers

**DISTINGUISHED CONTRIBUTION AWARD**  
 Chandru P. Sundaram, MD, MBA  
 For outstanding contributions in endourology and as a member of the AUA Board of Directors

**DISTINGUISHED SERVICE AWARD**  
 Toby C. Chai, MD  
 For exemplary contributions to the science of urology and advocacy for urological research

**DISTINGUISHED SERVICE AWARD**  
 Barbara B. Hartford  
 For innovative and impactful management of AUA finances, especially during the worldwide pandemic

**DISTINGUISHED SERVICE AWARD**  
 Janet V. Skorepa  
 For exemplary service in enriching AUA education, the Annual Meeting and member services

**DISTINGUISHED SERVICE AWARD**  
 Martha K. Terris, MD  
 For outstanding contributions to urological research and to the creation of the SEARCH database

**GOLD-HEADED CANE AWARD**  
 Julio M. Pow-Sang, MD, MBA  
 For a superlative career dedicated to advancing urological oncology, resident education and physician development

**PRESIDENTIAL CITATION**  
 Patricia M. Banks, MS  
 For outstanding leadership in advancing AUA programs during the worldwide pandemic

**PRESIDENTIAL CITATION**  
 Diane E. Bieri, Esq.  
 For outstanding service and teamwork in navigating AUA operations during the worldwide pandemic

**PRESIDENTIAL CITATION**  
 Christian G. Chaussy, MD  
 For world-renowned leadership and unsurpassed contributions in shock wave lithotripsy and high-intensity focused ultrasound

**PRESIDENTIAL CITATION**  
 Rodney Davis, MD  
 For dedicated military service and for outstanding contributions to minimally invasive techniques for the treatment of urological malignancies

**PRESIDENTIAL CITATION**  
 Inderbir S. Gill, MD, MCh  
 For scientific innovations in robotic and laparoscopic oncologic surgery

**PRESIDENTIAL CITATION**  
 Victor W. Nitti, MD  
 For outstanding contributions as the AUA Education Chair advancing the Urology Core Curriculum and AUA/University






  
**Jelmyto**<sup>®</sup>  
(mitomycin) for pyelocalyceal solution

# INNOVATION & INSPIRATION AWAIT

The experience starts here.



JELMYTO<sup>®</sup> and UroGen<sup>®</sup> are registered trademarks of UroGen Pharma, Ltd.  
© 2022 UroGen Pharma, Inc. All rights reserved.  
US-JEL-00407 03/22

# COMPETITION COMING TO ROBOTIC SURGICAL SYSTEMS

The world of robotic surgery is about to shift. Multiple new robotic surgical platforms have been approved or are in the approval pipeline, all with the promise of potential improvements in performance, cost or both over the current market-dominant leaders.

“Until very recently, for urology, robotic surgery has really meant the da Vinci® Surgical System from Intuitive Surgical,” said S. Duke Herrell, MD, FACS, professor of urological surgery and of biomedical and mechanical engineering at Vanderbilt University, and director of robotic surgery for Vanderbilt Medical Center in Nashville. “Intuitive Surgical has had first-mover advantage with massive

financial and market success around the world. We are just now finally seeing the first systems to challenge them emerge that have actually reached approval and use in several countries. It’s not just laparoscopic robotic systems, there is growth in new types of procedural-specific robotics such as flexible endoscopic robots and rigid endoscopic robots as well.”

Dr. Herrell will moderate the panel discussion “Laparoscopic Robotic Surgical Systems—Emerging Systems in Urology Use” on Monday from 9:05 to 9:50 a.m. Urologists from Asia, Europe and North America will discuss their personal experiences with new systems in clinical use.

Some of these new systems are very similar to the da Vinci® system in terms of design and underlying mechanisms, whereas others have significant differences, Dr. Herrell said, and all continue to evolve.



S. Duke Herrell, MD, FACS

What most urologists call surgical robots are truly “telepresence manipulators” that allow a surgeon to control instruments from a remote station that can be across the room or potentially a continent away. The technology underlying the da Vinci® system

was originally developed for remote surgery to help military surgeons deliver care in places they could not get to physically.

That same approach, manipulating wristed instruments at a distance guided by 3D camera vision for the surgeon, eased many of the barriers that had delayed the widespread adoption of laparoscopic surgery for complex urological surgeries. Every urologist has seen the impact that the da Vinci® system has had on day-to-day practice, urology training and patient expectations.

As Intuitive Surgical continues to roll out its own innovations,

competitors are developing and rolling out their own augmentations to image guidance and other key functions. There is also interest in automating surgical subtasks, which has already been done by orthopedic systems to improve drilling an area of bone for an implant.

“If a human sets up the robot properly and programs it correctly to perform a task that requires an immense amount of accuracy and precision and repetition, a robot can outperform a human—that’s why auto manufacturers have incorporated robots,” Dr. Herrell said. “What a robot doesn’t do well is deal with variation. If we can’t program a robotic car to reliably drive down the street in a complex scenario without running things over, we’re not ready to put a robot in charge in a complex surgical task.”

Even if surgical robots are not likely to replace surgeons in the near future, expect to see more robots in the operating room and interventional suites.


Pulmonologists are already using bronchoscopy robots to access lung masses for biopsy that are small and hard to localize with conventional bronchoscopes.

At least two companies are thought to be developing flexible robots that promise improvements on current generations of flexible ureteroscopes, Dr. Herrell noted. Another device manufacturer is developing a rigid endoscopic robot platform, deploying multiple 1-mm arms through a 26Fr scope for enucleation, en-bloc transurethral resection of bladder tumors (TURBT), hysteroscopy and other procedures that can benefit from retraction, precise tissue removal and tissue manipulation.

“Robotics has already changed the landscape and the practice of urology in dramatic ways,” Dr. Herrell said. “This session will explore the current state and competition that is emerging in the laparoscopic robot world, the kinds of robots that are already in use and hints of what is coming in other areas of urology.” ●

## Laparoscopic Robotic Surgical Systems—Emerging Systems in Urology Use

Monday, May 16  
9:05-9:50 a.m.  
Great Hall A




## Learn about a new era of patient and physician access to gallium-based PSMA PET imaging.

Visit Telix Pharmaceuticals at  
AUA 2022 in New Orleans

**Booth #655**

US-2200078 0422



Scan code with the  
camera on your  
mobile device to visit  
[galliumwave.com](http://galliumwave.com)



# WE PUT THE T IN ORAL SOFTGELS. LITERALLY.

## This is individualized testosterone replacement therapy in a form that fits him.

Join us in The JATENZONE (Booth 1507) to learn all about JATENZO.

ICU Theater: An Individualized Approach to Oral Testosterone Replacement Therapy

Parviz K. Kavoussi, MD, FACS

Reproductive Urologist

Austin Fertility & Reproductive Medicine | Westlake IVF | Austin, Texas

Sunday, May 15 from 2:30pm – 3:30pm

Scan the QR code or visit [JATENZOHCP.com](http://JATENZOHCP.com) to learn more.



### INDICATION

JATENZO® (testosterone undecanoate) capsules, CIII, is an androgen indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone:

- Primary hypogonadism (congenital or acquired): testicular failure due to cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome, orchiectomy, Klinefelter syndrome, chemotherapy, or toxic damage from alcohol or heavy metals. These men usually have low serum testosterone concentrations and gonadotropins (follicle-stimulating hormone [FSH], luteinizing hormone [LH]) above the normal range.
- Hypogonadotropic hypogonadism (congenital or acquired): gonadotropin or luteinizing hormone-releasing hormone (LHRH) deficiency or pituitary-hypothalamic injury from tumors, trauma, or radiation. These men have low testosterone serum concentrations but have gonadotropins in the normal or low range.

### Limitation of use

Safety and efficacy of JATENZO in males less than 18 years old have not been established.

### IMPORTANT SAFETY INFORMATION FOR JATENZO (testosterone undecanoate)

#### WARNING: INCREASES IN BLOOD PRESSURE

- **JATENZO can cause blood pressure (BP) increases that can increase the risk of major adverse cardiovascular events (MACE), including non-fatal myocardial infarction, non-fatal stroke and cardiovascular death.**
- **Before initiating JATENZO, consider the patient's baseline cardiovascular risk and ensure blood pressure is adequately controlled.**
- **Periodically monitor for and treat new-onset hypertension or exacerbations of pre-existing hypertension and re-evaluate whether the benefits of JATENZO outweigh its risks in patients who develop cardiovascular risk factors or cardiovascular disease on treatment.**
- **Due to this risk, use JATENZO only for the treatment of men with hypogonadal conditions associated with structural or genetic etiologies.**

### CONTRAINDICATIONS

JATENZO is contraindicated in men with carcinoma of the breast or known or suspected carcinoma of the prostate, in women who are pregnant, in men with a known hypersensitivity to JATENZO or its ingredients, or in men with hypogonadal conditions that are not associated with structural or genetic etiologies as JATENZO has not been established for these conditions and there is a risk of increased blood pressure with JATENZO that can increase the risk of MACE.

### WARNINGS AND PRECAUTIONS

- JATENZO can increase blood pressure, which can increase the risk of MACE, with greater risk in patients with established cardiovascular disease or risk factors for cardiovascular disease. Before initiating JATENZO, consider the patient's baseline cardiovascular risk and ensure blood pressure is adequately controlled. Monitor blood pressure approximately 3 weeks after initiating, increasing the dose, and periodically while on JATENZO, and treat any new or exacerbations of hypertension. Re-evaluate benefits and risks of continued treatment with JATENZO in patients who develop cardiovascular risk factors or disease. JATENZO is contraindicated in men with hypogonadal conditions such as "age-related hypogonadism" because the efficacy of JATENZO has not been established for these conditions and the increases in BP can increase the risk of MACE.
- Polycythemia may require a lower dose or discontinuation of JATENZO. Check hematocrit prior to initiation and every 3 months while a patient is on JATENZO and if hematocrit becomes elevated, stop JATENZO until hematocrit decreases to an acceptable level. If hematocrit increases after JATENZO is restarted, stop permanently.
- Some studies, but not all, have reported an increased risk of major adverse cardiovascular events (MACE) in association with use of testosterone replacement therapy in men. Long-term clinical safety trials have not been conducted to assess the cardiovascular outcomes of testosterone replacement therapy in men. Patients should be informed of this possible risk when deciding whether to use or to continue to use JATENZO. JATENZO can increase blood pressure, which can increase the risk of MACE.
- Monitor patients with benign prostatic hyperplasia (BPH) treated with androgens due to an increased risk for worsening signs and symptoms of BPH. Patients treated with androgens may be at increased risk for prostate cancer and should be evaluated prior to initiating and during treatment with androgens. Monitor prostate-specific antigen (PSA) levels periodically.
- Postmarketing reports of venous thromboembolic events (VTE), including deep vein thrombosis (DVT) and pulmonary embolism (PE), have been reported in patients using testosterone replacement products like JATENZO. Evaluate patients with signs or symptoms consistent with DVT or PE and, if a VTE is suspected, discontinue JATENZO and initiate appropriate workup and

management.

- Testosterone has been subject to abuse, typically at doses higher than recommended for the approved indication and in combination with other anabolic androgenic steroids. Anabolic androgenic steroid abuse can lead to serious cardiovascular and psychiatric adverse reactions. If abuse is suspected, check testosterone levels to ensure they are in therapeutic range. Counsel patients concerning the serious adverse reactions associated with abuse of testosterone and anabolic androgenic steroids. Conversely, consider the possibility of testosterone and anabolic androgenic steroid abuse in suspected patients who present with serious cardiovascular or psychiatric adverse events.
- JATENZO is not indicated for use in women.
- Large doses of androgens can suppress spermatogenesis by feedback inhibition of pituitary FSH. Inform patients of this risk before prescribing JATENZO.
- Prolonged use of high doses of methyltestosterone has been associated with serious hepatic adverse events. JATENZO is not known to cause these adverse events; however, patients should be instructed to report any signs of hepatic dysfunction and JATENZO should be discontinued while the cause is evaluated.
- Androgens, including JATENZO, may promote retention of sodium and water. Edema, with or without congestive heart failure, may be a serious complication in patients with pre-existing cardiac, renal, or hepatic disease. In addition to discontinuation of the drug, diuretic therapy may be required.
- Gynecomastia may develop and persist in patients being treated for hypogonadism.
- The treatment of hypogonadal men with testosterone may potentiate sleep apnea in some patients, especially those with risk factors such as obesity or chronic lung disease.
- Changes in the serum lipid profile may require dose adjustment of lipid-lowering drugs or discontinuation of testosterone therapy. Monitor the lipid profile periodically, particularly after starting testosterone therapy.
- Use JATENZO with caution in cancer patients at risk of hypercalcemia. Monitor serum calcium concentration regularly during treatment with JATENZO in these patients.
- Androgens, including JATENZO, may decrease concentrations of thyroxine-binding globulin, resulting in decreased total T4 serum concentrations and increased resin uptake of T3 and T4. Free thyroid hormone concentrations remain unchanged, however, and there is no clinical evidence of thyroid dysfunction.
- Depression and suicidal ideation have been reported in patients treated with JATENZO in clinical trials. Advise patients and caregivers to seek medical attention for manifestations of new-onset or worsening depression, suicidal ideation or behavior, anxiety, or other mood changes.

### ADVERSE EVENTS

The most common adverse events of JATENZO (incidence ≥2%) are headache (5%), increased hematocrit (5%), hypertension (4%), decreased HDL (3%), and nausea (2%).

### DRUG INTERACTIONS

- JATENZO can cause changes in insulin sensitivity or glycemic control. Androgens may decrease blood glucose and may require a decrease in the dose of antidiabetic medications.
- Anticoagulant activity may be affected by androgens. More frequent monitoring of international normalized ratio (INR) and prothrombin time are recommended in patients taking warfarin, especially at initiation and termination of androgen therapy.
- Use of testosterone and corticosteroids concurrently may increase fluid retention and requires monitoring in patients with cardiac, renal, or hepatic disease.
- Some prescription and nonprescription analgesic cold medications contain drugs known to increase blood pressure and concomitant use of these medications with JATENZO may lead to additional increases in blood pressure.

### USE IN SPECIFIC POPULATIONS

The safety and efficacy of JATENZO in pediatric patients less than 18 years old have not been established. Improper use may result in acceleration of bone age and premature closure of epiphyses.

There have not been sufficient numbers of geriatric patients involved in controlled clinical studies utilizing JATENZO to determine whether efficacy or safety in those over 65 years of age differs from younger subjects. There is insufficient long-term safety data in geriatric patients utilizing JATENZO to assess the potentially increased risk of cardiovascular disease and prostate cancer.

**Please see the full Prescribing Information on JATENZOPI.com, including BOXED WARNING on increases in blood pressure.**

**clarus**  
THERAPEUTICS

JATENZO® is a registered trademark of Clarus Therapeutics, Inc.  
© 2022 Clarus Therapeutics, Inc. All rights reserved. JTZ-US-2152 04/2022



## QUESTION OF THE DAY

What is the best thing about being back at AUA2022?



"It's the sheer amount of education and resources just concentrated in one place. In a way, I think our AUA website kind of has that with AUA University. As a resident, I use that frequently with the core curriculum and all that stuff, but to have it in person with everything at your fingertips is something I don't think we get very often and we certainly haven't had for the past two or three years of the pandemic."

Kiran Sury, MD  
Philadelphia, Pennsylvania



"The best part for me, at least, is to be back in person and to have those handshake connections and really get to see some people you haven't seen for a few years."

Ryan Nasser, MD  
San Diego, California



"It's to get to see all of the new technologies emerging. I'm very interested in minimally invasive surgery and I know a lot of that originated from urology and that's why I'm here."


Aya Bsate, DO  
Oak Park, Illinois


# VOICES&VIEWS

JOIN THE CONVERSATION ON TWITTER, AND INSTAGRAM #AUA22  



Muhieddine Labban  
@mdlabban

The 2022 #AQuilon team and alumni dinner at #AUA22 #NOLA  
Our strength lies in our #Diversity and representation 



Daaniya Jamal  
@DaaniyaJ

It is so humbling to be surrounded by innovations and improvements in clinical guidelines, noninvasive and invasive surgical procedures, equipment, and diagnostic parameters in both male and female urologic medicine @AmerUrological #AUA22 #MedTwitter



Ranjith Ramasamy  
@ranjithramamd

Social media superstars @justindubinmd @RenaMalikMD @LoebStacy @AdityaBagrodia informing the audience how to and not to navigate these various platforms. Such a relevant and important talk. #AUA22 #UroSoMe

KATIE MURRAY  
@KSMurrayUro

Amazing how many people I'm meeting for the first time in person that we feel like we have already known one another for years! #UroSoMe #collaborations @SUO\_YUO @AmerUrological #AUA22



Boston Scientific Urology  
and Pelvic Health  
@bsc\_urology

Have you stopped by the #AUA22 "Ins & Outs of Sexual Health" museum exhibit? Great info on the history of innovation in this important field! #womenshealth #menshealth

## PRODUCT SPOTLIGHT



**mediplus**

**Mediplus S-Cath™ System**  
Safer, more precise suprapubic catheterization

The Seldinger suprapubic catheter insertion kit

[www.s-cath.com](http://www.s-cath.com)



**MULTIPHZE**  
ENCLOSED BLADDER IRRIGATION SYSTEM

Introducing a Transformative Advancement in Urinary Bladder Irrigation

We're revolutionizing medical irrigation, challenging the old ways and bringing necessary change to keep it clean.

Visit us at Booth 859 for a hands-on demonstration

[multiphze.com](http://multiphze.com)



**Prostate MRI insights at expert level fueled by AI**

**BOOK A DEMO**

Visit us at booth 1944

**Quantib**



**Join ChristianaCare Urology!**

Why ChristianaCare?

- Treat patients at two ChristianaCare nearby campuses in Newark, Delaware, and Elton, MD.
- Conduct a wide array of surgical procedures including HOLEP, robotic nephrectomy, and TURP
- Enjoy access to two surgical robots on two state-of-the-art campuses and a large ACS verified simulation center
- Live in DE, NJ, PA or MD within 1-2 hours from Philadelphia, New York City and Washington, DC as well as the beautiful beach towns in DE, NJ and MD.
- Named among Forbes Best Employer for Diversity & Inclusion in The U.S. For 2021
- Mentor and precept ChristianaCare General Surgery residents

TO LEARN MORE PLEASE CONTACT FRANK GALLAGHER, SENIOR PHYSICIAN RECRUITER AT: [FRANK.GALLAGHER@CHRISTIANACARE.ORG](mailto:FRANK.GALLAGHER@CHRISTIANACARE.ORG)

[https://careers.christianacare.org/jobs/Urologist/Wilmington\\_Delaware/103/290747/](https://careers.christianacare.org/jobs/Urologist/Wilmington_Delaware/103/290747/)



# Introducing ENTADFI. FLOW HARD™

Faster and better relief of BPH symptoms  
without unwanted sexual side effects<sup>1,2\*</sup>

Visit us at booth 2059

## INDICATIONS AND USAGE

ENTADFI is a combination of finasteride, a 5 $\alpha$ -reductase inhibitor, and tadalafil, a phosphodiesterase 5 (PDE5) inhibitor, and, indicated to initiate treatment of the signs and symptoms of benign prostatic hyperplasia (BPH) in men with an enlarged prostate for up to 26 weeks.

## IMPORTANT SAFETY INFORMATION

### DOSAGE AND ADMINISTRATION

One capsule orally once daily at approximately the same time every day for up to 26 weeks. Take without food.

### DOSAGE FORMS AND STRENGTHS

Capsules: fixed dose combination containing finasteride 5 mg and tadalafil 5 mg.

### CONTRAINDICATIONS

- Concomitant use with any form of organic nitrate, either regularly and/or intermittently. ENTADFI can potentiate the hypotensive effect of nitrates.
- Known hypersensitivity to ENTADFI or any of its components.
- Pregnancy.
- Concomitant use with guanylate cyclase (GC) stimulators. ENTADFI may potentiate the hypotensive effects of GC stimulators.

### WARNINGS AND PRECAUTIONS

- Cardiovascular Risk: Administer nitrates concomitantly only in life-threatening situations under close medical supervision.
- Potential for Drug Interactions when taking ENTADFI: Use alpha-blockers, antihypertensives, strong CYP3A4 inhibitors and alcohol with caution due to the potential for symptomatic hypotension.
- Consideration of Other Urological Conditions Prior to Initiation of Treatment for BPH: Carefully monitor patients with large residual urinary volume and/or severely diminished urinary flow for obstructive uropathy. Prostate cancer and BPH may coexist.
- Effects of PSA and the Use of PSA in Prostate Cancer Detection: PSA reduction by approximately 50% within six months of treatment can be seen which can affect interpretation of serial and isolated PSA values. Evaluate any confirmed increase in PSA as it may signal the presence of prostate cancer.

- Increased Risk of High-Grade Prostate Cancer: Increased incidence of high-grade prostate cancer has been observed.
- Risk to Male Fetus from Topical ENTADFI Exposure to Pregnant Females: Pregnant women should not handle crushed or open ENTADFI capsules.
- Hypersensitivity Reactions: Immediately discontinue if a hypersensitivity reaction occurs.
- Prolonged Erection and Priapism: Use with caution in patients predisposed to priapism. Advise patients to seek emergency treatment if an erection lasts more than 4 hours.
- Ocular Adverse Reactions: Stop use in the event of a sudden loss of vision in one or both eyes. Such an event may be a sign of non-arteritic anterior ischemic optic neuropathy (NAION). Use with caution in patients at increased risk of NAION.
- Sudden Hearing Loss: Stop use and seek prompt medical attention.

### ADVERSE REACTIONS

Most common adverse reactions associated with finasteride monotherapy ( $\geq 1\%$ ) in a 4-year study were impotence, decreased libido, decreased volume of ejaculate, breast enlargement, breast tenderness, and rash.

Most common adverse reactions ( $\geq 2\%$ ) associated with tadalafil were headache, dyspepsia, back pain, myalgia, nasal congestion, flushing, and pain in limb.

To report SUSPECTED ADVERSE REACTIONS, contact Veru Inc. at 1-866-936-8233 or [www.verupharma.com](http://www.verupharma.com) or FDA at 1-800-FDA-1088 or [www.fda.gov/medwatch](http://www.fda.gov/medwatch).

### DRUG INTERACTIONS

CYP3A4 inducers: Concomitant use may increase tadalafil exposure. Use is not recommended.

### USE IN SPECIFIC POPULATIONS

#### Hepatic Impairment:

- Child's Pugh Class A and B: Use with caution.
- Child's Pugh Class C: Use is not recommended.

#### Renal Impairment:

- Creatinine clearance less than 50 mL/min or hemodialysis: Use is not recommended.

Please see full Prescribing Information at [ENTADFI.com/pi](http://ENTADFI.com/pi).

\*Compared to finasteride alone.

**References:** 1. Casabé A, Roehrborn CG, Da Pozzo LF, et al. Efficacy and safety of the coadministration of tadalafil once daily with finasteride for 6 months in men with lower urinary tract symptoms and prostatic enlargement secondary to benign prostatic hyperplasia. *J Urol*. 2014;191(3):727-733. doi:10.1016/j.juro.2013.09.059 2. ENTADFI. Prescribing information. Veru Inc.; 2022.



# UROVANT<sup>®</sup>

## SCIENCES

Makers of  **GEMTESA<sup>®</sup>**  
(vibegron) 75 mg tablets

**We look forward to connecting  
with you in person at this year's  
AUA meeting!**

Thank you for the feedback you've provided to help us bring  
an important treatment option to the market in 2021.

**Learn more about Urovant and how to find us at AUA**



**[Urovant.com/AUA](https://Urovant.com/AUA)**